Biopharmaceutical developers have initiated late-stage clinical trials for several messenger RNA (mRNA) and small interfering RNA (siRNA) candidates targeting previously untreatable metabolic conditions. The progress reflects significant improvements in lipid nanoparticle delivery systems.
Delivery Mechanism Optimization
Advanced lipid formulations now enable high organ-specificity, reducing off-target hepatic accumulation and minimizing patient side-effect profiles during clinical testing.
Manufacturing Scale and Cost
Contract development and manufacturing organizations (CDMOs) are investing heavily in automated enzymatic synthesis, aiming to reduce per-dose production costs by 35% over the next three years.